Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

Early Phase 1TerminatedNCT00361296

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins9 enrolled

Overview

RATIONALE: Vaccines made from cancer cells may help the body build an effective immune response to kill abnormal cells. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with myelodysplastic syndromes (MDS).

OBJECTIVES: Primary * Determine the safety of GM-K562 cell vaccine in patients with myelodysplastic syndromes. * Determine the hematologic and cytogenetic response in patients treated with this vaccine. Secondary * Determine if vaccination with GM-K562 cell vaccine can induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 \[WT-1\], survivin, or proteinase-3), as defined by a 30% increase from baseline in specific cytotoxic T-cells measured by Elispot assay, in patients with myelodysplastic syndromes. * Determine if immune response correlates with any clinical responses (e.g., hematologic response, resolution of cytogenetic abnormalities, or decrease in other parameters, such as WT-1 mRNA levels). OUTLINE: This is an open-label study. Patients receive GM-K562 cell vaccine subcutaneously once in weeks 0, 3, 6, 9, and 17 in the absence of disease progression or unacceptable toxicity. Blood and tissue samples are collected periodically for correlative and biomarker studies. Samples are analyzed by cytogenetic studies, fluorescent in situ hybridization (FISH), and flow cytometry. Elispot is used to quantify cellular cytotoxic T-cell response to Wilms' tumor-1 (WT-1), survivin, and proteinase 3. After completion of study treatment, patients are followed every 3 months for 1 year. PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Myelodysplastic Syndromes

Interventions

K562/GM-CSF cell vaccineBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Pathologically confirmed myelodysplastic syndromes (MDS), including any of the following: * Refractory anemia (RA) * RA with ringed sideroblasts * Refractory cytopenias with multilineage dysplasia (RCMD) * RCMD with ringed sideroblasts * RA with excess blasts 1 (5-9% blasts) * RA with excess blasts 2 (10-19% blasts) * Must have poor-risk MDS, defined by the following: * At least 2 lineages involved * Unfavorable cytogenetics (i.e., abnormalities of chromosome 5 or 7, 11q23, t\[6;9\], trisomy 8, inv3, or multiple/complex karyotype) * Transfusion requirement of \> 2 units of packed red blood cells monthly * No chronic myelomonocytic leukemia * No transformation to acute myeloid leukemia PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Creatinine \< 2.5 mg/dL * Bilirubin \< 2.5 mg/dL (unless due to Gilbert's syndrome) * Room air oxygen saturation ≥ 94% at rest * Fertile patients must use effective contraception * Negative pregnancy test * No other malignancy within the past 5 years except in situ cervical cancer or adequately treated nonmelanoma skin cancer * No active autoimmune disease or history of autoimmune disease requiring systemic immunosuppressants including, but not limited to, any of the following: * Autoimmune hemolytic anemia * Idiopathic thrombocytopenia purpura * Inflammatory bowel disease * Vasculitis * Thyroiditis * Rheumatic illnesses * No known HIV serum antibody positivity * No other disease requiring long-term corticosteroids or other immunosuppressants, such as severe chronic obstructive pulmonary disease or asthma PRIOR CONCURRENT THERAPY: * At least 2 weeks since prior systemic corticosteroids or other immunosuppressants (e.g., cyclosporine, azathioprine, tacrolimus, or mycophenolate mofetil) * At least 3 weeks since prior growth factors * At least 2 months since prior azacitidine for MDS * No prior bone marrow or other organ transplantation * No concurrent cytotoxic-based therapy for MDS * No other concurrent growth factors, including epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)

Locations (1)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Hematologic Response Rate as Assessed by Number of Participants Achieving a Major Hematologic Response

A major hematologic response is defined as any of the following: hemoglobin increase \>= 2 g/dL from baseline; platelet increase \>= 30k/mcL from baseline; or neutrophil increase \>= 100% or \>= 500/mcL from baseline.

Time frame: Baseline, week 21 post-intervention

Cytogenetic Response Rate as Assessed by Number of Participants Achieving a Cytogenetic Response

Cytogenetic response is defined as normalization of pretreatment cytogenetic abnormalities.

Time frame: Week 21

Secondary Outcomes

Immune Response Rate as Assessed by Number of Participants Who Exhibit Induced Immune Response to WT-1, Survivin, or Proteinase-3

Immune response to WT-1, survivin, or proteinase-3 as defined by a 30% increase from baseline in cytotoxic T cells measured by Elispot analysis.

Time frame: Baseline, week 21 post-intervention

Combined Immune and Clinical Response Rate

Number of participants who exhibited both an immune response as defined by Outcome 3 and a hematologic or cytogenetic response as defined by Outcomes 1 and 2, respectively.

Time frame: Week 21 post-intervention

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.